TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01001650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
Description: Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
Description: Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
Description: Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
Description: Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.
Study: NCT05748743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glove changing
Description: Surgical gloves were changed prior to abdominal closure during Cesarean section to evaluate its effectiveness in reducing wound complications after surgery
Study: NCT02038010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BYL719
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT03569410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: increased protein intake via natural foods
Description: Patients had to eat 1.4g/kg/day of natural protein.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: increase protein intake via protein supplements
Description: Patients ate enough protein supplements in addition to their regular diet to reach eat 1.4g/kg/day of protein intake.
Study: NCT04507399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid Model
Description: To study the perception of whey beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying)~Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein and whey permeate beverages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid Model
Description: To study the perception of whey beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying)~Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein and whey permeate beverages.
Study: NCT01750801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propolis
Description: Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
Study: NCT03182231

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT
Study: NCT01307332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MabCampath-1h
Description: Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
Study: NCT02445716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
Study: NCT04403724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl-Morphine.
Description: 2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl-Morphine.
Description: 2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
Study: NCT00962819

Intervention type: BIOLOGICAL
Intervention: MMR vaccine
Description: People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
Study: NCT02933164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Description: Effectiveness and safety of a Continuous Glucose Monitoring System
Study: NCT03995641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: marcaine and kenalog
Description: Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
Study: NCT00718874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: modification of macronutrient content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: modification of macronutrient content
Study: NCT01787292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Exercise Intervention
Description: A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Intervention
Description: Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Monitoring
Description: 6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
Study: NCT04196283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: Intratumoral (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: Intratumoral (IT) injection
Study: NCT00025883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Drug treatment
Study: NCT04413929

Intervention type: DRUG
Intervention: Ergoferon
Description: Oral administration
Study: NCT03806582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: intervention with norepinephrine to reach a MAP of 85 mmHg
Study: NCT01419405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill, saline infusion
Description: hard capsule, 150 mg, 2 times, 2 days, saline infusion
Study: NCT04129866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-IBM
Description: In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control-IBM
Description: Placebo IBM where sentences are not related to anxious threat meaning of cue word.
Study: NCT03710759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistive autogenic Drainage
Description: Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
Study: NCT02423057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TdCyd
Description: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
Study: NCT02919761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: 80 Units Acthar Gel per 1 mL for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: 80 Units Acthar Gel per 1 mL for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 1 mL for subcutaneous injection
Study: NCT02551341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: higher PEEP ventilation
Study: NCT02320929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative flexor tendon sheath irrigation
Study: NCT03072173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Description: Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
Study: NCT02987114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLT101
Description: PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
Study: NCT03072173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Description: Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (saline)
Description: Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (saline)
Description: Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
Study: NCT02320929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative flexor tendon sheath irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative flexor tendon sheath irrigation
Study: NCT03372265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Description: Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
Study: NCT01254799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg Doxycycline capsules twice daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice daily for 5 days
Study: NCT02983773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 7.2%
Description: 1 smoked marijuana cigarette with 7.2% THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 3.0%
Description: 1 smoked marijuana cigarette with 3.0% THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 smoked placebo marijuana cigarette
Study: NCT01002118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Acid Ethyl Esters
Description: 1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules each day for 16 weeks
Study: NCT05859893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical Turkish Music Sessions
Description: The participants attended an interactive livestreamed music performance. In selecting the mode, tempo, and songs to be performed, recommendations were obtained from the Applied Music Therapies Association, and the pieces with copyrighted recordings presented by the Edirne State Turkish Music Ensemble, under the leadership of the General Directorate of Fine Arts of the Ministry of Culture and Tourism. As part of the project, examples of traditional Turkish songs were presented to the elderly. The recommended genres and songs consist of vocal and instrumental works belonging to major and minor scales from the Classical Period, which spans from the 14th to the 20th century. In this respect an assembly of eight-musican consisting of five artists playing kanun, tanbur, ney, classical kemençe, and bendir, as well as two vocal soloists performed.
Study: NCT00901420

Intervention type: PROCEDURE
Intervention: Urodynamics Test
Description: 90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.

Intervention type: PROCEDURE
Intervention: Urodynamics Test
Description: 90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
Study: NCT01650194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
Study: NCT00901420

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
Study: NCT01650194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
Study: NCT00452790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 1 dose at 6, 10, 14 weeks and 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 valent pneumococcal conjugate vaccine
Description: 1 dose at 6, 10, 14 weeks and 12 months of age
Study: NCT01308697

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative fixation of flail chest
Description: Plate fixation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Operative management
Description: Non Operative treatment of Flail Chest
Study: NCT03621657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose FMT Capsule DE
Description: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose FMT Capsule DE
Description: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
Study: NCT00218543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
Study: NCT02919033

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-management
Description: * Usual care~* Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~* All patients receive proficiency training in using the BP tele-monitor, and mobile App.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCTM intervention
Description: * Usual care~* Self-management~* PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~* PCPs and cardiologists receive training of the CareLinker website.
Study: NCT01585480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Gain Prevention Intervention
Description: 1. Behavioral Approaches~   1. Distribution of pedometers~  2. Traffic light labeling in worksite cafeteria and vending machines~2. Informational \& Persuasive Messages~   1. Stair use prompts~  2. Posters, pamphlets, table toppers~  3. Website~3. Social Approaches~   a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~4. Environmental Changes~   1. Traffic light labeling~  2. 1/2 portions at 1/2 price~  3. Walking routes~  4. Introduction of healthier foods~  5. Rearrangement of foods in the cafeteria~  6. Adjusting serving spoon size
Study: NCT01864291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Description: Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
Study: NCT03621657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
Study: NCT01473732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
Study: NCT04464642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 25 mg subcutaneous is given in group A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tofacitinib 10 mg given in group B